Regulatory Effect of Modified Banxia Xiexintang on Insulin Resistance of Patients with Nonalcoholic Fatty Liver
10.13422/j.cnki.syfjx.20200833
- VernacularTitle:半夏泻心汤加减对非酒精性脂肪肝的临床疗效及对胰岛素抵抗的调节效果观察
- Author:
Yong-hua ZHAN
1
;
Xue-hong WANG
1
;
Fang WANG
1
Author Information
1. Affiliated Hospital of Qinghai University，Xining 810001，China
- Publication Type:Research Article
- Keywords:
nonalcoholic steatohepatitis;
disharmony of liver and stomach;
stagnation of dampness and turbidity;
Banxia Xiexintang;
insulin resistance;
HOMA-β cell;
adipocyte factor;
inflammatory factor
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(3):117-122
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical efficacy of modified Banxia Xiexintang on nonalcoholic fatty liver （NAFLD） and the regulatory effect on insulin resistance （IR）. Method:One hundred and forty patients were randomly divided into control group and observation group. A total of 63 patients in control group completed the therapy （4 patients fell off or were lost to follow-up， 3 were eliminated）， while 65 patients in observation group completed the therapy （5 patients fell off or were lost to follow-up， none was eliminated）. Both groups' patients got lifestyle intervention， liver protection and lipid regulation. Patients in control group got Huazhi Rougan granule， 1 pack/time， 3 times/day. Patients in observation group got modified Banxia Xiexintang， 1 dose/day. And the course of treatment for the two groups was 12 weeks， and a 12 week follow-up was recorded. Before and after treatment and during the follow-up， fat content of liver was recorded by instantaneous elastic recorder， fasting blood glucose （FBG） and fasting insulin （FINS） were detected， and insulin sensitivity index （ISI）， insulin resistance index （HOMA-IR） and islet β cell function index （HOMA-β） were detected. After treatment， B-mode ultrasonography and ratio of liver/spleen CT were detected. And levels of alanine transaminase （ALT）， aspartate transaminase （AST）， total cholesterol （TC）， triglyceride （TG）， high-density lipoprotein cholesterol （HDL-C）， low-density lipoprotein cholesterol （LDL-C）， adiponectin， leptin， serine protease inhibitor （Vaspin）， tumor necrosis factor （TNF）-α and interleukin-6 （IL-6） were detected. And the safety was evaluated. Result:CAP and HOMA-IR in observation group were lower than those in control group after treatment and during the follow-up （P<0.01）， and ISI and HOMA-β were higher than those in control group （P<0.01）. Amelioration of indexes of blood lipid was better than those in control group （P<0.01）. Levels of ALT， AST， FBG and FINS were lower than those in control group （P<0.01）. Scores of traditional Chinese medicine （TCM） syndromes were lower than those in control group （P<0.01）， ratio of liver/spleen CT and adiponectin was higher than that in control group （P<0.01）. Levels of TNF-α， IL-6， vaspin and leptin were lower than those in control group （P<0.01）. B-ultrasound efficacy and fat content of liver were superior to those of control group （P<0.05）. There were no serious adverse events and drug-related adverse reactions. Conclusion:Modified Banxia Xiexintang can regulate glucose and lipid metabolism， improve insulin sensitivity and HOMA-β cell function， improve IR， regulate adipocytokines and inflammatory factors， relieve clinical symptoms and liver fat content， and improve CT ratio of liver/spleen， with a better clinical efficacy and safety.
